Research

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials

Harold R Collard, Eric Yow, Luca Richeldi, Kevin J Anstrom and Craig Glazer

For all author emails, please log on.

Respiratory Research 2013, 14:73 doi:10.1186/1465-9921-14-73

Published: 13 July 2013

Abstract (provisional)

Background

Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.

Methods

Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.

Results

Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.

Conclusions

In this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.